The data comes from external studies that evaluated the potential clinical and workflow benefits of the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit compared to current methods. The studies also include new early stage research on potential whole blood applications.
ASM Microbe attendees can learn more about the potential impacts of faster antibiotic susceptibility results direct from positive blood cultures on patient treatment and antimicrobial stewardship at four Industry and Science presentations, two live and unscripted Q&A sessions with early clinical adopters, and ten poster presentations.
All presentations will be held at the ASM Microbe Annual Meeting
For schedule information, speaker details, and a list of poster presentations, visit http://acceleratediagnostics.com/asm2017.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" logos and marks are trademarks or registered trademarks of
Certain of the statements made in this press release are forward looking, such as those, among others, about the performance and potential clinical and workflow benefits of our products, and potential of future applications of our products. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned "Risk Factors" in the company's most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 28, 2017, and in any other reports that we file with the Securities and Exchange Commission from time to time. The company's forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.
Andrew Chasteen, Accelerate Diagnostics, firstname.lastname@example.org, +1 520 365-3100
Source: Accelerate Diagnostics, Inc.
News Provided by Acquire Media